Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Seeks To Cut Abbott Synthroid Distribution To 60% By August 2002

Executive Summary

An FDA guidance on levothyroxine products calls for Abbott to reduce Synthroid distribution to 60% of current levels by August 2002, about the time the company anticipates FDA approval for the drug.

Related Content

Forest Levothroid Misses NDA Approval Deadline; FDA Requests Withdrawal
King Tigan Suppository sNDA Pushed To 2004 Under Revised FDA Agreement
Digoxin Timelines: Unapproved Tablets Can Remain 30 Days, Elixirs Two Years
Abbott GMP Investments “Pay Off” In Pharma, Despite Diagnostics Setback
King Files 20 Levoxyl Patent Applications; Sales Up 65% to $27 Mil. In Q3
Synthroid market share "holding steady"
Levoxyl Prescription Growth Linked To FDA Levothyroxine Guidance - King
King Tigan Approval Expected In Six Months; Bioequivalence Data Submitted
Watson Unithroid promotions
Abbott Synthroid



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts